Fulcrum Therapeutics (FULC) — AI Analysis & Mentions

Fulcrum halted a major drug program after the FDA flagged cancer risk, and is now reviewing strategic options to preserve capital. This is a stark reminder that in speculative sectors like biotech, even promising data can be derailed by regulation, emphasizing the importance of a margin of safety.